Evidence map›Paper›PMID 27749933›Full record

ArticlePloS one2016

Afferent Visual Pathway Affection in Patients with PMP22 Deletion-Related Hereditary Neuropathy with Liability to Pressure Palsies.

Alexander U Brandt, Elena Meinert-Bohn, Jan Leo Rinnenthal, Hanna Zimmermann, Janine Mikolajczak, Timm Oberwahrenbrock, Sebastian Papazoglou, Caspar F Pfüller, Johann Schinzel, Björn Tackenberg and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Schizophrenia and Hereditary Polyneuropathy:Frontiers in psychiatry · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Alexander U BrandtNeuroCure Clinical Research Center, Charité -Universitätsmedizin Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0002-9768-014X
Elena Meinert-BohnNeuroCure Clinical Research Center, Charité -Universitätsmedizin Berlin, Berlin, Germany.
Jan Leo RinnenthalInstitute of Neuropathology, Charité -Universitätsmedizin Berlin, Berlin, Germany.
Hanna ZimmermannNeuroCure Clinical Research Center, Charité -Universitätsmedizin Berlin, Berlin, Germany.
Janine MikolajczakNeuroCure Clinical Research Center, Charité -Universitätsmedizin Berlin, Berlin, Germany.
Timm OberwahrenbrockNeuroCure Clinical Research Center, Charité -Universitätsmedizin Berlin, Berlin, Germany.
Sebastian PapazoglouNeuroCure Clinical Research Center, Charité -Universitätsmedizin Berlin, Berlin, Germany.
Caspar F PfüllerNeuroCure Clinical Research Center, Charité -Universitätsmedizin Berlin, Berlin, Germany.
Johann SchinzelNeuroCure Clinical Research Center, Charité -Universitätsmedizin Berlin, Berlin, Germany.
Björn TackenbergDepartment of Neurology, University of Giessen-Marburg, Marburg, Germany.
Friedemann PaulNeuroCure Clinical Research Center, Charité -Universitätsmedizin Berlin, Berlin, Germany.
Katrin HahnDepartment of Neurology, Charité -Universitätsmedizin Berlin, Berlin, Germany.
Judith Bellmann-StroblNeuroCure Clinical Research Center, Charité -Universitätsmedizin Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin · DEMax Delbrück Center · DEBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEJustus-Liebig-Universität Gießen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe PMP22 gene encodes a protein integral to peripheral myelin. Its deletion leads to hereditary neuropathy with liability to pressure palsies (HNPP). PMP22 is not expressed in the adult central nervous system, but previous studies suggest a role in CNS myelin development. The objective of this study was to identify potential structural and functional alterations in the afferent visual system in HNPP patients.

methodsTwenty HNPP patients and 18 matched healthy controls (HC) were recruited in a cross-sectional study. Participants underwent neurological examination including visual acuity, visual evoked potential (VEP) examination, optical coherence tomography (OCT), and magnetic resonance imaging with calculation of brain atrophy, regarding grey and white matter, and voxel based morphometry (VBM), in addition answered the National Eye Institute's 39-item Visual Functioning Questionnaire (NEI-VFQ). Thirteen patients and 6 HC were additionally examined with magnetic resonance spectroscopy (MRS).

resultsAll patients had normal visual acuity, but reported reduced peripheral vision in comparison to HC in the NEI-VFQ (p = 0.036). VEP latency was prolonged in patients (P100 = 103.7±5.7 ms) in comparison to healthy subjects (P100 = 99.7±4.2 ms, p = 0.007). In OCT, peripapillary retinal nerve fiber layer thickness RNFL was decreased in the nasal sector (90.0±15.5 vs. 101.8±16.5, p = 0.013), and lower nasal sector RNFL correlated with prolonged VEP latency (Rho = -0.405, p = 0.012). MRS revealed reduced tNAA (731.4±45.4 vs. 814.9±62.1, p = 0.017) and tCr (373.8±22.2 vs. 418.7±31.1, p = 0.002) in the visual cortex in patients vs. HC. Whole brain volume, grey and white matter volume, VBM and metabolites in a MRS sensory cortex control voxel did not differ significantly between patients and HC.

conclusionPMP22 deletion leads to functional, metabolic and macro-structural alterations in the afferent visual system of HNPP patients. Our data suggest a functional relevance of these changes for peripheral vision, which warrants further investigation and confirmation.

Indexed as

AdultArthrogryposisBrainCase-Control StudiesCross-Sectional StudiesEvoked Potentials, VisualFemaleGray MatterHereditary Sensory and Motor NeuropathyHumansMagnetic Resonance ImagingMaleMiddle AgedMyelin ProteinsRetinaSequence DeletionMyelin ProteinsPMP22 protein, human

Identifiers

PMID27749933
PMCPMC5066968
OpenAlexW2533641721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.